Article Text
Articles
▼Quinupristin + dalfopristin for infections
Relevant BNF section: 5.1.7
Abstract
▼Quinupristin + dalfopristin* (Synercid-Aventis Pharma Ltd) is a new combination antibacterial product licensed for treating patients with a variety of Gram-positive infections. Here we assess its place in clinical practice.
Statistics from Altmetric.com
Relevant BNF section: 5.1.7